SIGA TECHNOLOGIES INC (SIGAQ:OTCBB)

SIGA Technologies is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is TPOXX® (USAN tecovirimat, ST-246®), an orally administered antiviral drug that targets orthopoxvirus infections. TPOXX has been approved by the FDA for the treatment of human smallpox disease. It is a novel small-molecule drug that is being delivered to the Strategic National Stockpile under Project BioShield.

Yearly

Quarterly

FYE 12/31	2019	2018	2017	2016
(in thousands, except per share amounts)
Net Revenues	26,742	477,054	12,269	14,988
Net Income (Loss)	(7,241)	421,808	(36,235)	(39,698)
Net Income Percent Change	N/A	N/A	N/A	N/A
Profit Margin	N/A	88.42	N/A	N/A
Stockholders' Equity	97,784	102,915	(323,138)	(287,418)
Shareholders Equity Per Share	1.19	1.24	(4.10)	(5.03)
Return on Stockholders' Equity	N/A	N/A	N/A	N/A
Net Income Per Share	(0.15)	5.18	(0.46)	(0.69)
Average Shares Outstanding Diluted	82,175	82,708	78,874	57,189

Company Contact:
Name:	JAY VOSLER
Title:
Phone:	(212) 672-9107